GTx Inc. (Nasdaq: GTXI) reported that its prostate cancer treatment toremifene failed a late stage clinical study sending the stock price plummeting $1.00 to close at $2.02.
GTx Cancer Treatment Fails Study
May 26, 2010 at 18:13 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.